Invivyd, Inc. (NASDAQ:IVVD) Sees Large Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,980,000 shares, a growth of 8.4% from the December 15th total of 3,670,000 shares. Based on an average daily volume of 958,500 shares, the short-interest ratio is currently 4.2 days. Approximately 5.3% of the shares of the stock are sold short.

Insider Activity

In other Invivyd news, Director Terrance Mcguire sold 65,359 shares of Invivyd stock in a transaction on Monday, December 16th. The shares were sold at an average price of $0.47, for a total value of $30,718.73. Following the sale, the director now directly owns 4,012,320 shares in the company, valued at approximately $1,885,790.40. The trade was a 1.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 816,466 shares of company stock worth $423,214 in the last three months. Company insiders own 17.90% of the company’s stock.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd boosted its stake in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of Invivyd during the 3rd quarter worth about $27,000. Marshall Wace LLP boosted its stake in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares during the period. State Street Corp boosted its stake in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the period. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Stock Down 7.5 %

Shares of NASDAQ:IVVD opened at $0.41 on Tuesday. Invivyd has a 52 week low of $0.38 and a 52 week high of $5.20. The stock has a market capitalization of $48.61 million, a P/E ratio of -0.21 and a beta of 0.64. The firm has a fifty day simple moving average of $0.58 and a two-hundred day simple moving average of $0.88.

Wall Street Analysts Forecast Growth

IVVD has been the topic of a number of research reports. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright reduced their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Friday, January 10th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Invivyd presently has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.